Verona Pharma announces the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients.
With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much attention as it is on the verge of becoming the first biologic to treat chronic obstructive pulmonary disorder (COPD).
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at...
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (œVerona Pharma or the œCompany), announces it will hold an Investor Update in New York City for...
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and...
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its chronic obstructive pulmonary disease (COPD) maintenance drug, ensifentrine.
UK-based biotech Verona Pharma said Tuesday morning that its drug, ensifentrine, passed its second late-stage trial for the common lung disease COPD.
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD